✨ Free AI Report
NewAmsterdam Pharma Company N.V.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research NewAmsterdam Pharma Company N.V.
Company Research

NewAmsterdam Pharma Company N.V.: Business Overview, Financials & Competitive Analysis

NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address l...

Analyst-debate audio for NewAmsterdam Pharma Company N.V.

AskCyborg analysts argue the bull and bear cases for NewAmsterdam Pharma Company N.V. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Focused late-stage biotech with first-mover advantage in next-generation CETP inhibition and multi-indication potential, trading...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest NewAmsterdam Pharma Company N.V. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

NewAmsterdam Pharma Company N.V. Overview

Pro stress-test →

NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address limitations in current LDL cholesterol-lowering treatments, with clinical trials underway across cardiovascular and neurological indications.

Strategic Profile

Pro stress-test →

Trading at approximately 35x earnings multiples with significant upside potential, NewAmsterdam has built a focused pipeline around obicetrapib's mechanism. The company demonstrates strong analyst confidence (12 of 12 buy ratings) and trades substantially below peer valuation estimates, positioning it as a differentiated player in the competitive metabolic disease space.

Competitive Landscape

Pro stress-test →

NewAmsterdam competes in the cardiometabolic disease therapeutic space against established players developing CETP inhibitors and other LDL-lowering mechanisms. The company's low-dose oral formulation differentiates it from historical CETP inhibitors, positioning obicetrapib as next-generation therapy addressing unmet needs in statin-resistant populations.

Industry Context

NewAmsterdam Pharma Company N.V. operates in Biopharmaceutical / Clinical-Stage Drug Development.

Key facts

Headquarters: Naarden, Netherlands · Employees: 100 · Revenue: $22.5M · Market cap: $3.94B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on NewAmsterdam Pharma Company N.V..

  • Lead asset obicetrapib in late-stage development as monotherapy and combination therapy for LDL-C reduction in cardiovascular disease
  • Secondary indication in Phase 2a for Alzheimer's disease expands market opportunity beyond cardiology
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026European regulatory decision announcement for lead candidate
  • February 2026Analyst rerating with Guggenheim raising price target to $45 from $41
  • +1 moreTrack every material event for NewAmsterdam Pharma Company N.V. as it happens. Explore monitoring →
Get alerted when NewAmsterdam Pharma Company N.V. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CETP InhibitorsTraditional CETP inhibitor programs with different safety/efficacy profiles→PCSK9 InhibitorsEstablished LDL-lowering class with significant market penetration→GLP-1 AgonistsDominant cardiometabolic disease therapies with strong clinical evidence→

Compare NewAmsterdam Pharma Company N.V. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

NewAmsterdam Pharma Company N.V. operates in Biopharmaceutical / Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about NewAmsterdam Pharma Company N.V.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare NewAmsterdam Pharma Company N.V. and its top competitor on Cyborg Score”
“What did NewAmsterdam Pharma Company N.V. do this quarter?”
“Is NewAmsterdam Pharma Company N.V. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does NewAmsterdam Pharma Company N.V. do?+
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing next-generation therapies for cardiometabolic diseases. The company's lead asset, obicetrapib, is an oral CETP inhibitor positioned to address l...
What is NewAmsterdam Pharma Company N.V.'s Cyborg Score?+
NewAmsterdam Pharma Company N.V. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are NewAmsterdam Pharma Company N.V.'s main competitors?+
Named competitors include CETP Inhibitors, PCSK9 Inhibitors, GLP-1 Agonists. The full competitive landscape is in the AskCyborg report.
How can I get the full NewAmsterdam Pharma Company N.V. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the NewAmsterdam Pharma Company N.V. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track NewAmsterdam Pharma Company N.V. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score